Status:
COMPLETED
To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Infection
Pneumonia
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
To collect clinical response data with the use of ertapenem in approved indications.
Eligibility Criteria
Inclusion
- Male or female patients, 20 years of age or older
- Patients did not receive any systemic antibiotic before enrollment, or patients with failed clinical response (no improvement on symptoms or laboratory data) through previous antibiotic treatment
- Patients who required therapy prior to identification of cause of infection
Exclusion
- Patient has a concomitant infection that may interfere with the evaluation of the response to ertapenem
- Patient has an apache ii \> 30.
- Patient has an infection caused by pathogens resistant to ertapenem
- Patients with known allergy to ertapenem or other drugs in the same carbapenem class, beta - lactams, lidocaine or local anesthetics of the amide type
- The patient requires antibiotics other than ertapenem (such as: glycopeptides, macrolides or antifungal agents)
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
End Date :
January 1 2006
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00398099
Start Date
July 1 2005
End Date
January 1 2006
Last Update
February 17 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.